Keros Therapeutics/$KROS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
- Ticker
- $KROS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 92
- Headquarters
- Lexington, United States
- Website
- www.kerostx.com
KROS Metrics
BasicAdvanced
$225M
-
-$3.10
1.01
-
Price and volume
Market cap
$225M
Beta
1.01
52-week high
$22.55
52-week low
$9.69
Average daily volume
176K
Financial strength
Current ratio
21.96
Quick ratio
21.469
Long term debt to equity
0.05
Total debt to equity
0.06
Profitability
EBITDA (TTM)
-96.868
Gross margin (TTM)
-388.60%
Net profit margin (TTM)
-553.88%
Operating margin (TTM)
-655.84%
Effective tax rate (TTM)
3.41%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-11.78%
Return on equity (TTM)
-17.16%
Valuation
Price to revenue (TTM)
20.267
Price to book
0.86
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
-6.276
Free cash flow yield (TTM)
-15.93%
Free cash flow per share (TTM)
-1.81
Growth
Revenue change (TTM)
-93.55%
Earnings per share change (TTM)
-761.26%
3-year earnings per share growth (CAGR)
-12.05%
What the Analysts think about KROS
Analyst ratings (Buy, Hold, Sell) for Keros Therapeutics stock.
Analyst projections of the future price of Keros Therapeutics stock.
KROS Financial Performance
Revenues and expenses
KROS Earnings Performance
Company profitability
Upcoming events
No upcoming events
KROS News
AllArticlesVideos
Funds containing KROS
Fund name | Fund size | $KROS weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.02% |
iShares Ageing Population£AGES | $953M | 0.02% |
iShares Ageing Population€AGED | $903M | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.